title: Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection.
abstract: In this study, we tested the protective efficacy of recombinant Leishmania donovani iron superoxide dismutase B1 (SODB1) against Leishmania major infection in BALB/c mice. Mice were challenged with L. major 3weeks after the second boost immunization with rSODB1 alone or in the presence of adjuvants. Injection of BALB/c mice with rSODB1 alone elicited both humoral and cellular immune responses. Administration of rSODB1 with CpG ODN or GLA-SE (a synthetic toll-like receptor 4 agonist) adjuvant resulted in the induction of anti-SODB1 IgG1, and more importantly of significantly high levels of IgG2a isotype. Immunization of mice with rSODB1 alone or with adjuvant induced the production of IFN-γ by splenocytes in response to stimulation with L. major soluble leishmanial antigens (SLA). Moreover, immunization protocols involving rSODB1 resulted in a significant decrease in IL-10 as compared to controls. The presence of CpG ODN or GLA-SE adjuvant in the immunization protocols resulted in a relative increase in IFN-γ in response to stimulation with rSODB1 in comparison to immunization with rSODB1 alone. Mice immunized with rSODB1 plus CpG ODN or GLA-SE, were able to partially control their Leishmania infections, as indicated by the reduction in footpad swelling and parasite numbers, compared to controls. These results suggest that immunization with recombinant SODB1 protein together with CpG ODN or GLA-SE can be potential vaccine candidate against leishmaniasis.
authors.affiliation: University of Calgary, Department of Biological Sciences, Room 374, 2500 University Drive NW, Calgary, Alberta, Canada. nsdaifal@ucalgary.ca
authors.forename: Nada S
authors.initials: NS
authors.lastname: Daifalla
authors.forename: Abebe Genetu
authors.initials: AG
authors.lastname: Bayih
authors.forename: Lashitew
authors.initials: L
authors.lastname: Gedamu
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis; D000953:Antigens, Protozoan / Q000276:immunology; D005260:Female; D007106:Immune Sera / Q000276:immunology; D007111:Immunity, Cellular; D007117:Immunization, Secondary; D007074:Immunoglobulin G / Q000096:biosynthesis; D007371:Interferon-gamma / Q000096:biosynthesis; D016753:Interleukin-10 / Q000096:biosynthesis; D007893:Leishmania donovani / Q000201:enzymology* / Q000276:immunology*; D007898:Leishmaniasis, Visceral / Q000517:prevention & control*; D051379:Mice; D008807:Mice, Inbred BALB C; D016052:Protozoan Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000592:standards; D011897:Random Allocation; D011994:Recombinant Proteins / Q000276:immunology; D013047:Specific Pathogen-Free Organisms; D013154:Spleen / Q000166:cytology / Q000276:immunology; D013482:Superoxide Dismutase / Q000276:immunology*; D051193:Toll-Like Receptors / Q000008:administration & dosage / Q000819:agonists / Q000276:immunology*; D014614:Vaccines, Synthetic
chemical_list: D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D007106:Immune Sera; D007074:Immunoglobulin G; D016052:Protozoan Vaccines; D011994:Recombinant Proteins; D051193:Toll-Like Receptors; D014614:Vaccines, Synthetic; D016753:Interleukin-10; D007371:Interferon-gamma; D013482:Superoxide Dismutase